High-dose chemotherapy followed by autologous stem cell transplantation as a first-line therapy for high-risk primary breast cancer: A meta-analysis

PLoS ONE

Volumn 7, Issue 3, 2012, Pages

  Wang, Jing ^a   Zhang, Qiguo ^a   Zhou, Rongfu ^a   Chen, Bing ^a   Ouyang, Jian ^a  

^a THE AFFILIATED DRUM TOWER HOSPITAL OF NANJING UNIVERSITY MEDICAL SCHOOL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; HORMONE RECEPTOR; MELPHALAN; METHOTREXATE; MITOXANTRONE; PACLITAXEL; THIOTEPA;

AGE; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; DISEASE FREE SURVIVAL; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG MEGADOSE; HIGH RISK PATIENT; HUMAN; META ANALYSIS; OVERALL SURVIVAL; PREMENOPAUSE; PRIMARY TUMOR; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECOND CANCER; ADULT; AUTOTRANSPLANTATION; BREAST TUMOR; DRUG THERAPY; FEMALE; METHODOLOGY; MIDDLE AGED; MORTALITY; PROSPECTIVE STUDY; STATISTICAL MODEL; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

ADULT; BREAST NEOPLASMS; DRUG THERAPY; FEMALE; HUMANS; MIDDLE AGED; MODELS, STATISTICAL; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STEM CELL TRANSPLANTATION; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 84863277258     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0033388     Document Type: Article

References (38)

1. Jemal A, Siegel R, Xu J, Ward E, (2010) Cancer statistics, 2010. CA Cancer J Clin 60: 277-300.
2. Fisher ER, Fisher B, (1977) Relationship of pathologic and some clinical discriminants to the spread of breast cancer. Int J Radiat Oncol Biol Phys 2: 747-50.
3. Fisher ER, Redmond C, Fisher B, (1980) Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol no. 4). VI. Discriminants for five-year treatment failure. Cancer 46: 908-18.
4. Buzdar AU, Gutterman JU, Blumenschein GR, Hortobagyi GN, Tashima CK, et al. (1978) Intensive postoperative chemoimmunotherapy for patients with stage II and stage III breast cancer. Cancer 41: 1064-75.
5. Farquhar CM, Marjoribanks J, Lethaby A, Basser R, (2007) High dose chemotherapy for poor prognosis breast cancer: systematic review and meta-analysis. Cancer Treat Rev 33 (4): 325-37.
6. Ueno NT, Berry DA, Johnson MM, Lei X, Lopez VT, et al. (2008) High-dose chemotherapy with autologous stem-cell support versus standard-dose chemotherapy for high-risk breast cancer: meta-analysis of individual patient data from 15 randomized adjuvant trials. Biol Blood Marrow Transplant 14 (2): 91.
7. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, et al. (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 151 (4): W65-94.
8. Parmar MK, Torri V, Stewart L, (1998) Extracting summary statistics to performmeta-analyses of the published literature for survival endpoints. Stat Med 17: 2815-34.
9. Peters JL, Sutton AJ, Jones DR, Abrams KR, Rushton L, (2008) Contour-enhanced meta-analysis funnel plots help distinguish publication bias from other causes of asymmetry. J Clin Epidemiol 61 (10): 991-6.
10. Leonard RC, Lind M, Twelves C, Coleman R, van Belle S, et al. (2004) Conventional adjuvant chemotherapy versus single-cycle, autograft-supported, high-dose, late-intensification chemotherapy in high-risk breast cancer patients: a randomized trial. J Natl Cancer Inst 96 (14): 1076-83.
11. Peters WP, Rosner GL, Vredenburgh JJ, Shpall EJ, Crump M, et al. (2005) Prospective, randomized comparison of high-dose chemotherapy with stem-cell support versus intermediate-dose chemotherapy after surgery and adjuvant chemotherapy in women with high-risk primary breast cancer: a report of CALGB 9082, SWOG 9114, and NCIC MA-13. J Clin Oncol 23 (10): 2191-200.
12. Rodenhuis S, Richel DJ, van der Wall E, Schornagel JH, Baars JW, et al. (1998) Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement. Lancet 352 (9127): 515-21.
13. Tallman MS, Gray R, Robert NJ, LeMaistre CF, Osborne CK, et al. (2003) Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer. N Engl J Med 349 (1): 17-26.
14. Zander AR, Kröger N, Schmoor C, Krüger W, Möbus V, et al. (2004) High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial. J Clin Oncol 22 (12): 2273-83.
15. Basser RL, O'Neill A, Martinelli G, Green MD, Peccatori F, et al. International Breast Cancer Study Group (2006) Multicycle dose-intensive chemotherapy for women with high-risk primary breast cancer: results of International Breast Cancer Study Group Trial 15-95. J Clin Oncol 24 (3): 370-8.
16. Coombes RC, Howell A, Emson M, Peckitt C, Gallagher C, et al. (2005) High dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: long-term results of an international randomised trial. Ann Oncol 16 (5): 726-34.
17. Tokuda Y, Tajima T, Narabayashi M, Takeyama K, Watanabe T, et al. (2008) Phase III study to evaluate the use of high-dose chemotherapy as consolidation of treatment for high-risk postoperative breast cancer: Japan Clinical Oncology Group study, JCOG 9208. Cancer Sci 99 (1): 145-51.
18. Hortobagyi GN, Buzdar AU, Theriault RL, Valero V, Frye D, et al. (2000) Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma. J Natl Cancer Inst 92 (3): 225-33.
19. Rodenhuis S, Bontenbal M, Beex LV, Wagstaff J, Richel DJ, et al. (2003) High-dose chemotherapy with hematopoietic stem-cell rescue for high-risk breast cancer. N Engl J Med 349 (1): 7-16.
20. Bergh J, Wiklund T, Erikstein B, Lidbrink E, Lindman H, et al. (2000) Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study. Lancet 356 (9239): 1384-91.
21. Moore HC, Green SJ, Gralow JR, Bearman SI, Lew D, et al. (2007) Intensive dose-dense compared with high-dose adjuvant chemotherapy for high-risk operable breast cancer: Southwest Oncology Group/Intergroup study 9623. J Clin Oncol 25 (13): 1677-82.
22. Nitz UA, Mohrmann S, Fischer J, Lindemann W, Berdel WE, et al. (2005) Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial. Lancet 366 (9501): 1935-44.
23. Roche H, Viens P, Biron P, Lotz JP, Asselain B, (2003) High-dose chemotherapy for breast cancer: the French PEGASE experience. Cancer Control 10 (1): 42-7.
24. Gianni A, Bonadonna G, (2007) Updated 12-year results of a randomized clinical trial comparing standard-dose versus high-dose myeloablative chemotherapy in the adjuvant treatment of breast cancer with more than 3 positive nodes (LN+). Proc Am Soc Clin Oncol 25 (Abstract 549).
25. Schrama JG, Faneyte IF, Schornagel JH, Baars JW, Peterse JL, et al. (2002) Randomized trial of high-dose chemotherapy and hematopoietic progenitor-cell support in operable breast cancer with extensive lymph node involvement: final analysis with 7 years of follow-up. Ann Oncol 13 (5): 689-98.
26. Zander AR, Schmoor C, Kröger N, Krüger W, Möbus V, et al. (2008) Randomized trial of high-dose adjuvant chemotherapy with autologous hematopoietic stem-cell support versus standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: overall survival after 6 years of follow-up. Ann Oncol 19 (6): 1082-9.
27. Colleoni M, Sun Z, Martinelli G, Basser RL, Coates AS, et al. (2009) The effect of endocrine responsiveness on high-risk breast cancer treated with dose-intensive chemotherapy: results of International Breast Cancer Study Group Trial 15-95 after prolonged follow-up. Ann Oncol 20 (8): 1344-51.
28. Hanrahan EO, Broglio K, Frye D, Buzdar AU, Theriault RL, et al. (2006) Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma: follow-up at 12 years. Cancer 106 (11): 2327-36.
29. Rodenhuis S, Bontenbal M, van Hoesel QG, et al. (2006) Efficacy of high-dose alkylating chemotherapy in HER2/neu-negative breast cancer. Ann Oncol 17 (4): 588-96.
30. Wilking N, Lidbrink E, Wiklund T, Erikstein B, Lindman H, et al. (2007) Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrow-supported high-dose therapy. Ann Oncol 18 (4): 694-700.
31. Koreth J, Schlenk R, Kopecky KJ, Honda S, Sierra J, et al. (2009) Allogeneic stem cell transplantation for acute myeloid leukemia in first complete remission: systematic review and meta-analysis of prospective clinical trials. JAMA 301 (22): 2349-61.
32. George RE, Li S, Medeiros-Nancarrow C, Neuberg D, Marcus K, et al. (2006) High-risk neuroblastoma treated with tandem autologous peripheral-blood stem cell-supported transplantation: long-term survival update. J Clin Oncol 24 (18): 2891-6.
33. Attal M, Harousseau JL, Facon T, Guilhot F, Doyen C, et al. (2003) Single versus double autologous stem-cell transplantation for multiple myeloma. N Engl J Med 349: 2495-502.
34. Hutton JL, Williamson PR, (2000) Bias in meta-analysis due to outcome variable selection within studies. Appl Stat 49: 359-70.
35. Williamson PR, Marson AG, Tudur C, Hutton JL, Chadwick D, (2000) Individual patient data meta-analysis of randomized anti-epileptic drug monotherapy trials. J Eval Clin Pract 6 (2): 205-14.
36. Goldhirsch A, Glick JH, Gelber RD, Coates AS, Thürlimann B, et al. (2005) Meeting Highlights: International Expert Consensus on the Primary Therapy of Early Breast Cancer 2005. Ann Oncol 16: 1569-83.
37. Nieto Y, Shpall EJ, (2009) High-dose chemotherapy for high-risk primary and metastatic breast cancer: is another look warranted? Curr Opin Oncol 21 (2): 150-7.
38. Jüni P, Witschi A, Bloch R, Egger M, (1999) The hazards of scoring the quality of clinical trials for meta-analysis. JAMA 282 (11): 1054-60.